CFTR and cystic fibrosis: Moreover, ivacaftor, the only potentiator drug to be approved so far for clinical use in CF patients, acts by promoting such spontaneous, ATP-independent, openings of G551D CFTR, the third most common disease mutant (Bompadre et al., 2007; Jih et al., 2013).